MicroRNAs 对肺癌靶向治疗耐药性的研究进展

分子靶向药物广泛应用于肺癌和其他恶性肿瘤的治疗，已成为治疗晚期肺癌患者的重要选择。 然而，肺癌细胞对分子靶向药物产生的耐药性，会限制肺癌的治疗效果，成为影响肺癌预后的主要原因。很多 因子如药物代谢相关基因和信号通路的变化都与肺癌细胞的耐药性有关。其中，MicroRNAs（miRNAs）的多 态性与肺癌细胞药物代谢和分子靶向药物耐药性的形成密切相关。对特定miRNAs 表达的调节将成为攻克肺 癌耐药性和个体化治疗的新途径。笔者系统阐述miRNAs 在肺癌细胞对分子靶向药物形成耐药性中的作用及 在肺癌靶向治疗中的潜在影响。

Research progress of microRNAs in resistance to targeted treatments of lung cancer

Molecular target therapy has been widely used in the treatment of lung cancer and other malignant tumors, and represents the mainstay of treatment for patients with advanced lung cancer. However, the emergence of drug resistance has been the main challenge for successful treatment of lung cancer. Many drug metabolism related genes and signal pathways have been implicated to be involved in drug resistance. The increasing number of studies have shown that miRNA polymorphisms associate with drug metabolism and resistance. It is believed that targeting specific miRNA expression represents a promising strategy to overcome drug resistance in lung cancer treatments. Here, we provide our up-to-date understanding of the roles of miRNAs in drug resistance of molecular target therapy, and their potential implications of lung cancer treatments.